Expansion of Swindon-based Wasdell Group and the continued development of their quality control laboratory services has led to the ongoing development of their quality department.
Their latest recruit, Qualified Person Raj Gaur, has been instrumental in the international development of the business, leading on the establishment of the Group’s quality testing laboratory in their Dundalk premises.
The laboratory is an extension of Wasdell’s UK-based service in testing pharmaceutical products to ensure that they meet regulatory standards and so are safe and consistent for the general public.
Raj joined Wasdell in Swindon in September 2020 with 27 years of experience in the pharmaceutical industry, including roles such as Associated Director of Quality, Head of Quality, Qualified Person and RP(I). In this time, he has set up two other laboratories from scratch and worked across the UK, Ireland and India.
In order to successfully establish the Dundalk lab, which has now been approved by the Irish Authority and HPRA and is fully functional, Raj specified the scientific instruments required, as well as the necessary quality management system and standard operating procedures, which are the backbone of every pharmaceutical set up.
As a Qualified Person, Raj is part of the Wasdell team responsible for certifying each batch of a pharmaceutical product and ensuring that it meets all required regulatory provisions when released from a manufacturing facility within the EU, or imported into the EU.
Raj explained: “Joining Wasdell has given me opportunities in the distribution and manufacturing and packaging areas of the industry. It was attractive to be part of a growing quality team, which will be approaching 40 people across Swindon and Dundalk by the end of the year. The combination of international expansion opportunities, plus the ability to work flexibly has made the move to Wasdell the right choice for me.
“Wasdell Dundalk is a fantastic, modern and sophisticated facility that allows us to develop our services and overcome issues posed by Brexit. This is a very exciting time for Wasdell as we continue to develop our offering in both the UK and Ireland, including testing and supporting clinical trials of new pharmaceutical products, and also now with the capacity and expertise to add and develop new services according to our clients’ needs.”
There are currently opportunities at Wasdell for Quality Control, Stability Study and Validation staff who have a background in the chemical and pharmaceutical industries. For more information on Wasdell, visit www.wasdell.com
